To identify additional resistance mechanisms and to avoid the above confounding factors, we selected the HER2+ breast cancer cell lines BT474, SKBR3, and UACC812, which are known to possess neither of those alterations. The gene discussed is ERBB2; the disease is breast carcinoma.